Targeting B cells for treatment of systemic sclerosis
Authors:
- 3 August 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 35 (6) , 317-323
Abstract
Purpose of review: The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the various aspects of B cell involvement in SSc. Recent findings: We provide an overview of the current understanding and therapeutic strategies targeting B cells in SSc patients. Several molecular targets of B cells have been identified for treating SSc, including CD20, CD19, B-cell activating factor (BAFF), and proteasome. Summary: Many clinical trials have demonstrated that B cells play a critical role in the pathogenesis of SSc and may be a potential therapeutic target to improve disease symptoms. Although large-scale clinical studies are needed, various B cell-targeted therapies have the potential to address the unmet needs of SSc patients.Keywords
This publication has 53 references indexed in Scilit:
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trialArthritis Research & Therapy, 2010
- Proteasomal Regulation of Pulmonary FibrosisProceedings of the American Thoracic Society, 2010
- Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological studyAnnals of the Rheumatic Diseases, 2010
- Bortezomib attenuates murine collagen-induced arthritisAnnals of the Rheumatic Diseases, 2009
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced SclerodermaThe American Journal of Pathology, 2008
- Ubiquitin: tool and target for intracellular NF-κB inhibitorsTrends in Immunology, 2006
- BAFF Overexpression Is Associated with Autoantibody Production in Autoimmune DiseasesAnnals of the New York Academy of Sciences, 2005